Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice

Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Angie C.A., Fowler, Stephanie W., Savjani, Ricky R., Hilsenbeck, Susan G., Wallace, Clare E., Cirrito, John R., Das, Pritam, Jankowsky, Joanna L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940263/
https://www.ncbi.nlm.nih.gov/pubmed/29626114
http://dx.doi.org/10.1084/jem.20171484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940263/
https://www.ncbi.nlm.nih.gov/pubmed/29626114
http://dx.doi.org/10.1084/jem.20171484

Ejemplares similares